



Published in final edited form as:

*Matern Child Health J.* 2015 May ; 19(5): 1097–1106. doi:10.1007/s10995-014-1611-z.

## Prevalence of Prescription Medication Use among Non-Pregnant Women of Childbearing Age and Pregnant Women in the United States – NHANES, 1999 – 2006

Sarah C. Tinker<sup>1</sup>, Cheryl S. Broussard<sup>1</sup>, Meghan T. Frey<sup>1,2</sup>, and Suzanne M. Gilboa<sup>1</sup>

<sup>1</sup>National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

<sup>2</sup>Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA

### Abstract

**Objectives**—Many prescription medications have limited information regarding safety for use during pregnancy. In order to inform research on safer medication use during pregnancy, we examined prescription medication use among women in the United States.

**Methods**—We analyzed data from the 1999–2006 National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of prescription medication use in the past 30 days among pregnant women and non-pregnant women of childbearing age (15–44 years) and to ascertain the most commonly reported prescription medications by women in these groups. We assessed how the most commonly reported medications differed among groups defined by selected demographic characteristics, including age, race/ethnicity, and markers of socioeconomic status.

**Results**—Prescription medication use in the past 30 days was reported by 22% of pregnant women and 47% of non-pregnant women of childbearing age. The most commonly reported prescription medications by NHANES participants differed somewhat by pregnancy status; allergy and anti-infective medications were more common among pregnant women, while oral contraceptives were more common among non-pregnant women. Use of prescription medication for asthma and thyroid disorders was reported by both groups.

**Conclusions**—Although prescription medication use in the previous 30 days was less common among pregnant women than non-pregnant women, its use was reported among almost 1 in 4 pregnant women. Many of the most common medications reported were for the treatment of chronic medical conditions. Given the potential impact of medications on the developing fetus, our data underscore the importance of understanding the safety of these medications during pregnancy.

### Keywords

medication; pregnancy; women; prescription; NHANES

## INTRODUCTION

Treating medical conditions in pregnant women is complicated by the need to balance the potential risk of medication exposures to the developing fetus with the potential risks to the health of the mother and the fetus if a condition is not treated. In order to weigh these risks, women and health care providers need to have reliable information on the safety of medication use during pregnancy. Substantial research gaps regarding medication safety during pregnancy have been well documented (1–5). A key step to guide this research is to characterize medication use among pregnant women and women capable of becoming pregnant (often operationalized as non-pregnant women of childbearing age). Many European countries have documented the prevalence of medication dispensing in their populations using robust population-wide registry data sources (6–11). Capturing medication exposure information for the U.S. population must rely on data from multiple data sources, each with unique strengths and limitations.

Some North American-based data sources, primarily population-based case-control studies and health plan database studies, have documented the prevalence of medication use during pregnancy, from 60% up to nearly 90%, and an increase in medication use over time (12–14). The prevalence of medication use among non-pregnant women of childbearing age is not well-understood. Understanding medication use among this population is important because 51 percent of pregnancies in the U.S. are unintended (15) and many pregnancies are not recognized early in the first trimester (16) when organogenesis occurs (17). A survey of an adult population in the U.S. conducted in 1998–1999 found that 82% of women age 18–44 years reported any use of a prescription or over-the-counter medication or a vitamin, mineral, or herbal supplement; results were not stratified by pregnancy status, however (18).

Our objective for the current investigation was to examine the prevalence of prescription medication use among women in the National Health and Nutrition Examination Survey (NHANES), a nationally representative cross-sectional survey (19–22). Because NHANES oversampled pregnant women in 1999–2006 (23), we were able to estimate prevalence of prescription medication use among both pregnant women and non-pregnant women of childbearing age and to identify the most commonly reported prescription medications used in the past 30 days by each group.

## METHODS

### Data Source

We analyzed data from NHANES, an ongoing, multistage sample survey used to monitor the health and nutritional status of the U.S. civilian, non-institutionalized population. Detailed methods for NHANES are provided elsewhere (19–22). Briefly, NHANES consists of an in-person interview and a physical examination. NHANES is currently conducted annually, and data are publicly released in two-year cycles. Data for this analysis came from the 1999 – 2006 cycles. All study participants provided informed consent, and the study protocol received approval from the National Center for Health Statistics Ethical Review Board.

During the interview participants were asked, “In the past month, have you used or taken medication for which a prescription is needed?” Participants reporting prescription medication use were then asked to show the prescription medication container, if available, so that the interviewer could record relevant information; no exclusions were made based on availability of the prescription container. Reported medications were classified using Cerner Multum’s Lexicon Plus® drug database. Dietary supplements reported in response to this question were not included in the analysis.

We used the NHANES variable “RIDEXPRG” to ascertain pregnancy status. A woman was coded as pregnant if she reported being pregnant in the questionnaire or if she tested positive during a urine pregnancy test. We included data from the 1999 – 2006 cycles because during this time period pregnant women were oversampled in NHANES, providing sufficient statistical stability to make nationally representative estimates. All pregnant women screened during these years were included in the survey. Beginning in the 2007 – 2008 survey cycle, pregnant women were no longer oversampled, and the number of pregnant women included in the survey population dropped dramatically. We defined non-pregnant women of childbearing age as those women who did not report being pregnant or test positive on the pregnancy test and who were age 15 to 44 years (only 6 pregnant women were outside of this age range); the term “non-pregnant women” will be used to refer to this group. Women for whom pregnancy status could not be determined were excluded (N=743).

## Analysis

Analyses were stratified by pregnancy status. Because research has shown that fetal effects of medication use during pregnancy may differ among various medications within a particular class (24), our study focused on specific medications rather than on broader medication classes or anatomical classification codes. We identified the reported prescription medication products by their generic drug names. We did not distinguish between different salts of the same active ingredient and combined all insulin-containing medications. We calculated the appropriate 8-year sampling weights (25). We estimated the distribution of the total number of prescription medications reported and determined which prescription medications were most commonly reported. We estimated the percentage of non-pregnant women that used each of these medications. Sample size was not sufficient to allow us to report these percentages for pregnant women, or to compare the percentages of pregnant and non-pregnant women that reported using specific medications. We identified the five most common medications reported among non-pregnant women stratified by categories defined by age, race/ethnicity, education level, poverty income ratio (PIR, defined as the ratio of self-reported family income to federal poverty threshold, accounting for family size, year, and state; higher values indicate higher socioeconomic status (26)), parity, and breastfeeding status; we were not able to consider these categories for pregnant women due to limited sample size. Analyses were conducted in SAS-callable SUDAAN version 11 (Research Triangle Institute, Research Triangle Park, NC, USA) using the “SDMVPSU” and “SDMVSTRA” variables for the masked variance pseudo-primary sampling unit and masked variance pseudo-stratum, respectively, to account for the complex survey design in our estimation of variance.

## RESULTS

The 1999 – 2006 NHANES included data on 1,350 pregnant women and 5,484 non-pregnant women. Based on weighted percentages, over half of the pregnant women were between the ages of 25 and 34, with fewer than 15% of women in this group age 35 years or older. In contrast, almost 40% of non-pregnant women were age 35 years or older. A higher percentage of non-pregnant women were non-Hispanic white, and a higher percentage of pregnant women were Mexican American. We observed little difference in the highest level of education attained or PIR category among pregnant and non-pregnant women. Not including their current pregnancy, pregnant women were more likely to have had a previous pregnancy than non-pregnant women. Among non-pregnant women, 2.5% reported that they were currently breastfeeding. Among pregnant women who self-reported that they were pregnant, approximately 24% reported being in their first trimester, 40% in their second trimester, and 36% in their third trimester (Table 1).

Prescription medication use in the past 30 days was reported among 22.2% of pregnant women (95% CI: 19.0%, 25.8%); non-pregnant women reported prescription medication use approximately twice as frequently (47.0%, 95% CI: 45.0%, 49.0%) (Figure 1). Among pregnant women who reported prescription medication use in the past 30 days, 72.8% (95% CI: 61.7%, 81.6%) reported use of only one medication. Among non-pregnant women who reported prescription medication use in the previous 30 days, about half reported use of one medication (47.7%, 95% CI: 45.7%, 49.8%) and half reported the use of two or more (52.3%, 95% CI: 50.2%, 54.4%). We were not able to further categorize the non-pregnant women reporting 2 or more medications (e.g. 2 vs. 3 or more) because of small numbers.

Among pregnant women the most commonly reported medication was levothyroxine, which is used to treat thyroid disorders. Three antibiotics – amoxicillin, nitrofurantoin, and the combination of sulfamethoxazole and trimethoprim – were among the most common prescription medications used by pregnant women. Certain asthma and allergy medications were also among the most commonly reported prescription medications; specifically albuterol, montelukast, cetirizine, budesonide, and promethazine, the last of which is more commonly prescribed for nausea and vomiting. Insulin was also among the 10 most frequently reported medications taken in the previous 30 days among pregnant women (Table 2). We were not able to estimate the percentage of pregnant women taking these medications, or compare these percentages to the percentages for non-pregnant women, due to small sample size.

Among non-pregnant women the most commonly reported prescription medication used in the previous 30 days was the combination of ethinyl estradiol and norgestimate, an oral contraceptive, use of which was reported by 3.7% of women in this group (95% CI: 2.9%, 4.7%). Two other oral contraceptives – the combination of ethinyl estradiol and norethindrone and the combination of ethinyl estradiol and levonorgestrel – were also among the 10 most commonly reported prescription medications used in the previous 30 days by non-pregnant women, used by 2.7% and 2.2%, respectively. Three selective serotonin reuptake inhibitors (SSRIs), used to treat conditions including depression and anxiety, were among the most commonly reported medications for non-pregnant women,

each reported by approximately 2% of women in this group. Pain relievers, specifically prescription-strength ibuprofen, used by 2.7% (95% CI: 2.2%, 3.4%), and the combination of acetaminophen and hydrocodone, used by 2.2% (95% CI: 1.7%, 2.8%), were also among the 10 prescription medications most commonly reported by non-pregnant women (Table 2).

Only levothyroxine and albuterol were included in the list of the 10 most commonly reported prescription medications used in the past 30 days among both pregnant women and non-pregnant women. Levothyroxine was reported by 3.4% (95% CI: 2.7%, 4.3%), and albuterol was reported by 2.9% (95% CI: 2.3%, 3.6%) of non-pregnant women.

For non-pregnant women, oral contraceptives were more often in the top five reported prescription medications among younger women, women with higher education, women in a higher PIR category, non-Hispanic white women, and nulliparous women. Norethindrone, a progestin-only oral contraceptive, was in the list of the five most common medications for breastfeeding women. Prescription pain medications and albuterol were present among the five most common medications for the majority of sociodemographic categories considered. For non-pregnant women age 35 to 44 years levothyroxine and fluoxetine were among the five most commonly reported prescription medications. Non-Hispanic white women were the only racial/ethnic group with SSRIs among the five most commonly reported medications. Hydrochlorothiazide, an antihypertensive, was reported only in the list of the five most common medications for non-Hispanic blacks; amoxicillin was reported only among the top five most common medications for Mexican Americans, and cetirizine, an antihistamine, was reported only in the list of the most common medications for the “other” racial/ethnic category (Table 3).

## DISCUSSION

We observed that reported prescription medication use in the past 30 days was half as common among pregnant women compared to non-pregnant women, and pregnant women who reported prescription medication use were more likely to report use of only one prescription medication. These differences have several possible explanations. Approximately 17% of U.S. women age 15–44 years used oral contraceptives in 2006–2008 (27), but given that these medications are designed to prevent pregnancy they are contraindicated and rarely used during pregnancy. Women may discontinue medication use upon pregnancy recognition, healthcare providers may be less likely to prescribe medications to pregnant women, or pregnant women may be less likely to take prescribed medications (28–30). In a survey of obstetrician gynecologists, Morgan and colleagues found that almost 50% of survey respondents reported that they did not prescribe medications to treat certain maternal conditions because of lack of data on medication safety (31). Pregnant women may assume that over-the-counter (OTC) medications are safer than prescription medications and may manage symptoms with OTC medications not captured in this analysis. Werler and colleagues reported increased prevalence of use for specific OTC medications during pregnancy when compared to the three months before pregnancy (14). Lastly, the fact that in our sample non-pregnant women were generally older than pregnant women could help to explain their higher medication use; older age is associated with increased prescription medication utilization (32, 33).

Differences in the types of medications most frequently reported by pregnant and non-pregnant women were also observed. Oral contraceptives were the most frequently reported prescription medications among non-pregnant women, comprising three of the 10 most common medications reported by this group. This observation is consistent with previously published reports that oral contraceptives are the most frequently used prescription medications among U.S. women age 18–44 years (18, 27). As expected, oral contraceptives were not among the most commonly used medications among pregnant women during the past 30 days. We conducted a sensitivity analysis in which oral contraceptives were excluded. Fexofenadine, an allergy medication, amoxicillin, an antibiotic, and bupropion, a medication used to treat depression or for smoking cessation, were then included in the list of 10 most common medications taken by this group.

We observed other noteworthy differences in medications used between pregnant and non-pregnant women. Pain medications and SSRIs were among the most commonly reported medications by non-pregnant woman, but not by pregnant women. This difference may indicate reluctance on the part of healthcare providers to prescribe medications for certain clinical indications during pregnancy (31). The use of opioid pain medications among women in the U.S. is a growing concern, with a 415% increase in overdose deaths between 1999 and 2010 (34). A recent analysis showed that the proportion of pregnant women covered by Medicaid who filled prescriptions for an opioid during pregnancy increased from 18.5% in 2000 to 22.8% in 2007 (35). Though not among the most commonly used medications during pregnancy, the use of opioid pain medications during pregnancy is also of concern due to the challenges of treating neonatal abstinence syndrome (36, 37) and the potential for increased risk of certain birth defects (selected heart defects, spina bifida, and gastroschisis) (38). Insulin was one of the most common medications reported by pregnant women, which is likely related to its use in managing gestational diabetes, which is estimated to occur in 2 – 10% of pregnancies (39). Some of the differences we observed may reflect uncertainty on the part of healthcare providers on how best to weigh the risks and benefits of medication use during pregnancy. Differences in sociodemographic characteristics, particularly age, may also contribute to differences in patterns of prescription medication use.

The frequently reported use of albuterol and levothyroxine in both groups of women suggests that asthma and certain thyroid conditions are among the more prevalent chronic conditions requiring prescription medication for woman of childbearing age. In an analysis of multiple national health surveys using data from 1997–2001, the prevalence of current asthma was estimated to be between 3.7%–8.3% and 5.0%–9.4%, among pregnant women and non-pregnant women of childbearing age, respectively(40). Previously published studies report the prevalence of overt hypothyroidism in pregnancy to be 1.4%–2.2% (41–44). Both untreated asthma and hypothyroidism have been associated with maternal and fetal complications (45–48). In addition, physiological and endocrine changes throughout pregnancy may increase symptom frequency or severity necessitating close clinical monitoring to maintain the efficacy of a given treatment throughout gestation (49–51). The prevalence of medication use to treat these conditions highlights the importance of understanding the safety profile of these medications during pregnancy and how best to manage these conditions in pregnant women.

Previously published studies report a higher prevalence of prescription medication use during pregnancy than was observed in our analysis, 64%–70% (12, 13). Several factors likely contributed to the lower prevalence of use that we observed (22%), with the greatest being that the time period of use queried in NHANES was only the previous 30 days, rather than the entire pregnancy. In addition, in the current analysis medication use was recorded based on women's self-report in response to a single question within a structured interview. Previous studies have utilized data from multiple medication-specific questions or large health maintenance organization prescription databases. However, our results regarding the most commonly reported prescription medications used during pregnancy are similar to results in previously published reports (5, 12, 13).

This analysis contributes to the literature by providing updated prevalence estimates for recent prescription medication use among a nationally representative sample of non-pregnant women of childbearing age. A 1998–1999 U.S. survey found that 46% of women 18–44 years of age reported using at least one prescription medication within the past week (18). Similar to our findings, oral contraceptives, levothyroxine, albuterol, and SSRIs were among the most frequently reported prescription medications in that study. Medication use among non-pregnant women of childbearing age is important to understand because over half of pregnancies are unintended according to 2008 U.S. data (15). Pregnancy recognition can take several weeks (16) and therefore understanding prescription utilization patterns among non-pregnant women of childbearing age is important to anticipating unintentional medication exposures during the first trimester, a critical time of organogenesis (17).

We observed notable differences in patterns of contraceptive use among non-pregnant women (Table 3). When stratified by race/ethnicity, oral contraceptives were reported among the five most commonly reported prescription medications only for non-Hispanic white women. Previous studies have reported that reproductive health service utilization varies by sociodemographic characteristics; in particular, non-white women are less likely to use contraceptives overall and use different contraceptive methods than non-Hispanic white women (27, 52). Contraceptive methods that do not require a prescription (e.g. condoms) or long-acting reversible contraceptive methods (e.g., subdermal contraceptive implant) would not be captured in our results. In addition, previous studies have reported that non-white women have higher rates of chronic disease, including asthma, diabetes, and hypertension (46, 53, 54). Therefore, non-white women may report using a greater total number of prescription medications compared to non-Hispanic white women, obscuring the frequency of oral contraceptive use among these groups in our analysis.

A strength of the current analysis is that the NHANES data are from a nationally representative, population-based sample of U.S. pregnant and non-pregnant women. NHANES oversampled pregnant women during the 1999–2006 survey cycles. The large number of non-pregnant women in our sample allowed us to estimate the prevalence of use of specific medications and to identify the most commonly reported medications among subgroups of this population.

This study was subject to certain limitations. Information on prescription medication use in the previous 30 days was based on self-report. However, prescription medication containers

were checked by trained interviewers which may have improved the accuracy of reported prescriptions, and the data captured reflect medications actually taken by the women, rather than relying on prescription dispensation records. In addition, the fact that participants were asked to recall only a short time period (30 days) may have assisted with accuracy. However, because participants were only queried about the previous 30 days, we were not able to assess prescription medication use throughout pregnancy. Because of the limitation to the previous 30 days, our results for the medications used by pregnant women are likely to underrepresent medications to treat acute symptoms or illnesses and are more likely to represent maintenance medications that are taken routinely. Pregnant women in their first trimester were also underrepresented in the NHANES sample because women had to be aware of their pregnancy status to be oversampled and included in the survey. Although the sample size was sufficient to estimate the percentage of pregnant women who reported taking a prescription medication in the past 30 days, the NHANES sample size was not sufficient to estimate the percentage of pregnant women taking specific medications or to allow for comparisons between these percentages in pregnant and non-pregnant women. Given that the total number of pregnant NHANES participants reporting each medication was relatively small (all  $N < 25$ ), the list of the most common medications should be interpreted with caution. Another limitation of the NHANES data is that it does not capture use of OTC medications, which is also important when considering exposure and safety during pregnancy.

In 2013 the Centers for Disease Control and Prevention convened an expert meeting to develop a systematic approach for evaluating and synthesizing existing data on medication use in pregnancy (55). This initiative, called Treating for Two, seeks to prevent adverse pregnancy outcomes related to maternal health conditions during pregnancy and to improve maternal health by providing women and their health care provider with the information they need for clinical decision making (see <http://www.cdc.gov/pregnancy/meds/treatingfortwo/>). Gaps in knowledge identified by the proposed review process could help to set a research agenda for conditions and medications that are important to investigate in the future. Given the observed prevalence of prescription medication use in pregnant women and non-pregnant women of childbearing age, our data support the need for further studies investigating the safety profile of medications commonly used during pregnancy and among non-pregnant women of childbearing age. It will be important to repeat analyses of this nature with other U.S. data sources and to track trends and detect changing usage patterns as new medications come onto the market. Our findings document the importance of developing a broad evidence base with sufficient data to inform clinical decision-making and a need for accessible clinical guidelines to treat common conditions during pregnancy.

## Acknowledgments


This work was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

## References

1. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. *American journal of medical genetics Part C, Seminars in medical genetics*. 2011; 157(3):175–82.
2. Lagoy CT, Joshi N, Cragan JD, et al. Medication use during pregnancy and lactation: an urgent call for public health action. *Journal of women's health*. 2005; 14(2):104–9.
3. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. *Obstetrics and gynecology*. 2002; 100(3):465–73. [PubMed: 12220765]
4. Mitchell AA. Systematic identification of drugs that cause birth defects--a new opportunity. *The New England journal of medicine*. 2003; 349(26):2556–9. [PubMed: 14695418]
5. Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. *Pharmacoepidemiology and drug safety*. 2013; 22(9):1013–8. [PubMed: 23893932]
6. Artama M, Gissler M, Malm H, et al. Nationwide register-based surveillance system on drugs and pregnancy in Finland 1996–2006. *Pharmacoepidemiology and drug safety*. 2011; 20(7):729–38. [PubMed: 21626607]
7. Bakker MK, Jentink J, Vroom F, et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. *BJOG : an international journal of obstetrics and gynaecology*. 2006; 113(5):559–68. [PubMed: 16637899]
8. Bjorn AM, Norgaard M, Hundborg HH, et al. Use of prescribed drugs among primiparous women: an 11-year population-based study in Denmark. *Clinical epidemiology*. 2011; 3:149–56. [PubMed: 21607016]
9. Daw JR, Hanley GE, Greyson DL, et al. Prescription drug use during pregnancy in developed countries: a systematic review. *Pharmacoepidemiology and drug safety*. 2011; 20(9):895–902. [PubMed: 21774029]
10. Espnes MG, Borge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. *Pharmacoepidemiology and drug safety*. 2011; 20(3):243–8. [PubMed: 21351305]
11. Stephansson O, Granath F, Svensson T, et al. Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register. *Clinical epidemiology*. 2011; 3:43–50. [PubMed: 21386973]
12. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. *American journal of obstetrics and gynecology*. 2004; 191(2):398–407. [PubMed: 15343213]
13. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. *American journal of obstetrics and gynecology*. 2011; 205(1):51 e1–8. [PubMed: 21514558]
14. Werler MM, Mitchell AA, Hernandez-Diaz S, et al. Use of over-the-counter medications during pregnancy. *American journal of obstetrics and gynecology*. 2005; 193(3 Pt 1):771–7. [PubMed: 16150273]
15. Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001–2008. *American journal of public health*. 2014; 104(Suppl 1):S43–8. [PubMed: 24354819]
16. Ayoola AB, Nettleman MD, Stommel M, et al. Time of pregnancy recognition and prenatal care use: a population-based study in the United States. *Birth*. 2010; 37(1):37–43. [PubMed: 20402720]
17. Sadler, TW. *Langman's Medical Embryology*. Baltimore, MD: Wolters Kluwer Health; 2011.
18. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. *JAMA : the journal of the American Medical Association*. 2002; 287(3):337–44. [PubMed: 11790213]
19. National Center for Health Statistics. [Accessed December 31, 2012 2012] National Health and Nutrition Examination Survey -- NHANES 1999–2000. 2012. ([http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/nhanes99\\_00.htm](http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/nhanes99_00.htm))
20. National Center for Health Statistics. [Accessed December 31, 2012 2012] National Health and Nutrition Examination Survey -- NHANES 2001–2002. 2012. ([http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/nhanes01\\_02.htm](http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/nhanes01_02.htm))

21. National Center for Health Statistics. [Accessed December 31, 2012 2012] National Health and Nutrition Examination Survey -- NHANES 2003–2004. 2012. ([http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03\\_04.htm](http://www.cdc.gov/nchs/nhanes/nhanes2003-2004/nhanes03_04.htm))
22. National Center for Health Statistics. [Accessed December 31, 2012 2012] National Health and Nutrition Examination Survey -- NHANES 2005–2006. 2012. ([http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05\\_06.htm](http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm))
23. Mirel, LB.; Curtin, LR.; Gahche, J., et al. JSM Proceedings, Section on Government Statistics. Alexandria, VA: American Statistical Association; 2009. Characteristics of pregnant women from the 2001–2006 National Health and Nutrition Examination Survey; p. 2592-602.
24. Mitchell, AA. Studies of drug-induced birth defects. In: Strom, BL., editor. Pharmacoevidence. New York, NY: John Wiley & Sons; 2005.
25. Curtin LR, Mohadjer LK, Dohrmann SM, et al. The National Health and Nutrition Examination Survey: Sample Design, 1999–2006. Vital and Health Statistics. 2012; 2(155)
26. National Center for Health Statistics. [Accessed August 30, 2013 2013] National Health and Nutrition Examination Survey: 1999–2000 Data Documentation, Codebook, and Frequencies - Demographic Variables and Sample Weights (DEMO). 2013. (<http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/DEMO.htm>)
27. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital and health statistics Series 23, Data from the National Survey of Family Growth. 2010; (29):1.
28. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. Journal of psychiatry & neuroscience : JPN. 2001; 26(1):44–8. [PubMed: 11212593]
29. Matsui D. Adherence with drug therapy in pregnancy. Obstetrics and gynecology international. 2012; 2012:796590. [PubMed: 22242026]
30. Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications? Epidemiology. 2001; 12(5):497–501. [PubMed: 11505166]
31. Morgan MA, Cragan JD, Goldenberg RL, et al. Management of prescription and nonprescription drug use during pregnancy. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2010; 23(8):813–9.
32. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief. 2010:42.
33. Salganicoff, A.; Ranji, UR.; Wyn, R. Women and health care: A national profile: Key findings from the Kaiser women's health survey. Henry J. Kaiser Family Foundation; 2005.
34. Mack KA, Jones CM, Paulozzi LJ. Vital Signs: Overdoses of prescription opioid pain relievers and other drugs among women - United States, 1999–2010. Morbidity and Mortality Weekly Report. 2013; 62(26):537–42. [PubMed: 23820967]
35. Desai RJ, Hernandez-Diaz S, Bateman BT, et al. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstetrics and gynecology. 2014; 123(5):997–1002. [PubMed: 24785852]
36. Sauber-Schatz EK, Mack KA, Diekmann ST, et al. Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits, and neonatal abstinence syndrome in Florida. Drug and alcohol dependence. 2013 Epub ahead of print.
37. Williams B. Drug-dependent at birth: neonatal abstinence syndrome in Tennessee. Tennessee medicine : journal of the Tennessee Medical Association. 2013; 106(3):22–6. [PubMed: 23544286]
38. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. American journal of obstetrics and gynecology. 2011; 204(4):314 e1–11. [PubMed: 21345403]
39. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.

40. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. *Annals of epidemiology*. 2003; 13(5):317–24. [PubMed: 12821270]
41. Allan WC, Haddow JE, Palomaki GE, et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. *Journal of medical screening*. 2000; 7(3): 127–30. [PubMed: 11126160]
42. Browne ML, Rasmussen SA, Hoyt AT, et al. Maternal thyroid disease, thyroid medication use, and selected birth defects in the National Birth Defects Prevention Study. *Birth defects research Part A, Clinical and molecular teratology*. 2009; 85(7):621–8.
43. Mannisto T, Mendola P, Grewal J, et al. Thyroid Diseases and Adverse Pregnancy Outcomes in a Contemporary US Cohort. *The Journal of clinical endocrinology and metabolism*. 2013; 98(7): 2725–33. [PubMed: 23744409]
44. Mannisto T, Mendola P, Reddy U, et al. Neonatal Outcomes and Birth Weight in Pregnancies Complicated by Maternal Thyroid Disease. *American journal of epidemiology*. 2013; 178(5):731–40. [PubMed: 23666815]
45. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. *Obstetrics and gynecology*. 2002; 100(2):387–96. [PubMed: 12166417]
46. Misra DP, Grason H, Weisman C. An intersection of women's and perinatal health: the role of chronic conditions. *Women's Health Issues*. 2000; 10(5):256–67. [PubMed: 10980443]
47. Namazy JA, Murphy VE, Powell H, et al. Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes. *The European respiratory journal*. 2013; 41(5):1082–90. [PubMed: 22903964]
48. Vissenberg R, van den Boogaard E, van Wely M, et al. Treatment of thyroid disorders before conception and in early pregnancy: a systematic review. *Human reproduction update*. 2012; 18(4): 360–73. [PubMed: 22431565]
49. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. *The New England journal of medicine*. 1994; 331(16):1072–8. [PubMed: 8090169]
50. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. *Seminars in perinatology*. 2001; 25(3):120–3. [PubMed: 11453606]
51. Goodrum LA, Hankins GD, Jermain D, et al. Conference report: complex clinical, legal, and ethical issues of pregnant and postpartum women as subjects in clinical trials. *Journal of women's health*. 2003; 12(9):857–67.
52. Dehlendorf C, Grumbach K, Vittinghoff E, et al. A study of physician recommendations for reversible contraceptive methods using standardized patients. *Perspectives on sexual and reproductive health*. 2011; 43(4):224–9. [PubMed: 22151509]
53. Ahluwalia IB, Mack KA, Mokdad A. Report from the CDC. Changes in selected chronic disease-related risks and health conditions for nonpregnant women 18–44 years old BRFSS. *Journal of women's health*. 2005; 14(5):382–6.
54. Schiller JS, Ward BW, Freeman G, et al. Early release of selected estimates based on data from the 2012 National Health Interview Survey. *National Center for Health Statistics*. 2013
55. Broussard CS, Frey MT, Hernandez-Diaz S, et al. Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention-convened meeting. *American journal of obstetrics and gynecology*. 2014



**Figure 1.** Distribution of the number of prescription medications reported to have been taken in the previous 30 days among U.S. pregnant women and non-pregnant women of childbearing age, National Health and Nutrition Examination Survey (NHANES), 1999–2006

**Table 1**  
 Characteristics of U.S. non-pregnant women of childbearing age and pregnant women participating in the National Health and Nutrition Examination Survey (NHANES) 1999–2006

	Non-pregnant women aged 15–44 years		Pregnant women	
	N <sup>a</sup>	Percentage <sup>b</sup>	N <sup>a</sup>	Percentage <sup>b</sup>
Total	5484	100	1350	100
Age group (years)				
<25	2781	31.1 (29.4, 32.8)	546	34.3 (30.7, 38.0)
25–34	1239	30.0 (28.0, 32.0)	676	51.3 (46.7, 55.9)
35+	1464	39.0 (36.8, 41.2)	128	14.4 (11.0, 18.7)
Race/ethnicity				
Non-Hispanic white	2056	65.3 (61.9, 68.6)	599	54.9 (49.1, 60.6)
Non-Hispanic black	1427	13.4 (11.3, 15.8)	211	15.9 (12.3, 20.3)
Mexican American	1520	9.4 (7.9, 11.2)	395	15.9 (13.0, 19.3)
Other race/ethnicity	481	11.9 (9.8, 14.4)	145	13.3 (9.3, 18.6)
Education				
Less than high school	2324	24.3 (22.7, 25.9)	424	23.3 (19.7, 27.3)
High school	1111	22.4 (20.7, 24.1)	300	19.6 (16.1, 23.6)
More than high school	2044	53.3 (51.0, 55.6)	624	57.2 (52.6, 61.6)
Missing	5		2	
Poverty Income Ratio <sup>c</sup>				
0–1.30	1891	26.9 (24.6, 29.3)	436	26.8 (22.7, 31.4)
1.31–3.50	1875	36.9 (34.7, 39.1)	442	38.2 (34.3, 42.2)
3.51	1356	36.3 (33.7, 38.9)	373	35.0 (30.2, 40.2)
Missing	362		99	
Parity				
0	2571	40.7 (38.3, 43.3)	402	34.6 (29.3, 40.3)
1+	2415	59.3 (56.8, 61.8)	759	65.4 (59.7, 70.7)
Missing	498		189	
Breastfeeding Status				
Reported currently breastfeeding	177	2.5 (1.9, 3.3)	N/A	

	Non-pregnant women aged 15–44 years		Pregnant women	
	N <sup>a</sup>	Percentage <sup>b</sup>	N <sup>a</sup>	Percentage <sup>b</sup>
Did not report currently breastfeeding	5307	97.5 (96.7, 98.2)		
Trimester <sup>d</sup>				
1	N/A		210	23.8 (20.0, 28.1)
2			446	40.0 (35.1, 45.1)
3			413	36.2 (31.1, 41.6)
Missing <sup>e</sup>			281	

<sup>a</sup> Unweighted

<sup>b</sup> Weighted; accounted for complex survey design

<sup>c</sup> Poverty income ratio is an index for the ratio of family income to poverty, using poverty guidelines from the Department of Health and Human Services (23).

<sup>d</sup> Pregnant women were oversampled in the 1999–2006 NHANES survey cycles. All pregnant women screened were included in the survey. A woman had to know that she was pregnant to report it in the screening questionnaire, and therefore there are fewer women in their first trimester in these cycles of NHANES because if they didn't know they were pregnant they could not be oversampled into the survey.

<sup>e</sup> Trimester of pregnancy was ascertained through the reproductive questionnaire, and only asked of women who attended the Mobile Examination Center (MEC) and who reported that they were currently pregnant. 76 women who were pregnant did not attend the MEC; 154 women who were pregnant and attended the MEC did not answer the question as to whether they were currently pregnant, and were therefore not asked for their month of pregnancy; 4 women who responded that they were currently pregnant reported that they did not know their month of pregnancy; 37 women who were pregnant reported that they were not pregnant, and therefore were not asked for the month of their pregnancy (they were identified as pregnant through the urine test); 10 women reported that they did not know if they were currently pregnant, and they were not asked for their month of pregnancy

**Table 2**

Most commonly reported prescription medications used in the previous 30 days among non-pregnant women of childbearing age (15–44 years) and pregnant women in the National Health and Nutrition Examination Survey (NHANES), 1999–2006

Rank <sup>a</sup>	Medication	Number of women reporting use <sup>b</sup>	Percentage of women reporting use <sup>c</sup>	Typical indication
<b>Non-pregnant women age 15–44 y</b>				
1	Ethinyl estradiol/norgestimate <sup>d</sup>	155	3.7 (2.9, 4.7)	Contraception
2	Levothyroxine	115	3.4 (2.7, 4.3)	Thyroid disorder
3	Albuterol	149 <sup>e</sup>	2.9 (2.3, 3.6)	Asthma
4	Ibuprofen (prescription strength)	124 <sup>e</sup>	2.7 (2.2, 3.4)	Pain
5	Ethinyl estradiol/norethindrone <sup>d</sup>	96	2.7 (2.1, 3.4)	Contraception
6	Ethinyl estradiol/levonorgestrel <sup>d</sup>	83	2.2 (1.6, 2.9)	Contraception
7	Acetaminophen/hydrocodone <sup>d</sup>	94 <sup>e</sup>	2.2 (1.7, 2.8)	Pain
8	Fluoxetine	64	2.1 (1.6, 2.7)	Depression/Anxiety
9	Sertraline	73	1.9 (1.5, 2.3)	Depression/Anxiety
10	Paroxetine	60	NE <sup>f</sup>	Depression/Anxiety
<b>Pregnant women</b>				
1	Levothyroxine	24	NE <sup>f</sup>	Thyroid disorder
2	Amoxicillin	21		Infection
3	Insulin	12 <sup>e</sup>		Diabetes
4	Nitrofurantoin	26		Infection
5	Albuterol	28		Asthma
6	Promethazine	13		Nausea/Allergy
7	Cetirizine <sup>g</sup>	8		Allergy
8	Montelukast	5		Asthma/Allergy
9	Sulfamethoxazole/trimethoprim <sup>d</sup>	4		Infection
10	Budesonide	2		Asthma/Allergy

<sup>a</sup>Rank based on weighted number of women reporting use

<sup>b</sup>Unweighted

<sup>c</sup>Weighted; accounted for complex survey design

<sup>d</sup>Combination product

<sup>e</sup>8 women reported albuterol twice; 1 woman reported ibuprofen twice; 1 woman reported acetaminophen; hydrocodone twice; 7 women reported insulin twice

<sup>f</sup>Not estimable; the degrees of freedom were less than 12 and the relative standard error was >30%

<sup>g</sup>Became available without a prescription in 2006

Five most commonly reported prescription medications used in the previous 30 days<sup>d</sup> among selected categories of non-pregnant women of childbearing age (15–44 y) in the National Health and Nutrition Examination Survey (NHANES), 1999–2006

Table 3

<b>AGE GROUP</b>	
15–25 years	25–34 years
Ethinyl estradiol/norgestimate <sup>b</sup>	Ethinyl estradiol/norgestimate <sup>b</sup>
Albuterol	Ethinyl estradiol/norethindrone <sup>b</sup>
Ibuprofen	Albuterol
Ethinyl estradiol/norethindrone <sup>b</sup>	Ethinyl estradiol/levonorgestrel <sup>b</sup>
Ethinyl estradiol/levonorgestrel <sup>b</sup>	Ibuprofen
	35–44 years
	Levothyroxine
	Fluoxetine
	Ibuprofen
	Acetaminophen/hydrocodone <sup>b</sup>
	Albuterol
<b>RACE/ETHNICITY</b>	
<i>Non-Hispanic white</i>	<i>Mexican American</i>
Ethinyl estradiol/norgestimate <sup>b</sup>	Ibuprofen
Levothyroxine	Levothyroxine
Ethinyl estradiol/norethindrone <sup>b</sup>	Albuterol
Ibuprofen	Hydrochlorothiazide
Fluoxetine	Metformin
	Amoxicillin
	Cetirizine <sup>c</sup>
<b>EDUCATION LEVEL</b>	
<i>Less than high school</i>	<i>High school graduate or GED<sup>d</sup></i>
Albuterol	Albuterol
Ibuprofen	Levothyroxine
Paroxetine	Ethinyl estradiol/norgestimate <sup>b</sup>
Ethinyl estradiol/norgestimate <sup>b</sup>	Acetaminophen/hydrocodone <sup>b</sup>
Acetaminophen/hydrocodone <sup>b</sup>	Sertraline
<b>POVERTY INCOME RATIO (PIR)<sup>e</sup></b>	
0 PIR 1.30	1.31 PIR 3.50
Albuterol	Levothyroxine
	Ethinyl estradiol/norgestimate <sup>b</sup>
	PIR 3.51
	Ethinyl estradiol/norgestimate <sup>b</sup>

Ibuprofen	Ethinyl estradiol/norgestimate <sup>b</sup>	Levothyroxine
Acetaminophen/hydrocodone <sup>b</sup>	Ibuprofen	Ethinyl estradiol/norethindrone <sup>b</sup>
Ethinyl estradiol/norgestimate <sup>b</sup>	Ethinyl estradiol/norethindrone <sup>b</sup>	Ethinyl estradiol/levonorgestrel <sup>b</sup>
Sertraline	Acetaminophen/hydrocodone <sup>b</sup>	Fluoxetine
<b>PARITY</b>		
<i>Nulliparous</i>		
Ethinyl estradiol/norgestimate <sup>b</sup>	<i>Parous</i>	
Ethinyl estradiol/norethindrone <sup>b</sup>	Levothyroxine	
Albuterol	Ibuprofen	
Ethinyl estradiol/levonorgestrel <sup>b</sup>	Albuterol	
Sertraline	Acetaminophen/hydrocodone <sup>b</sup>	
	Fluoxetine	
<b>REPORTED BREASTFEEDING STATUS</b>		
<i>Currently breastfeeding</i>		
Ibuprofen	<i>Not currently breastfeeding</i>	
Levothyroxine	Ethinyl estradiol/norgestimate <sup>b</sup>	
Acetaminophen/oxycodone <sup>b</sup>	Levothyroxine	
Norethindrone	Albuterol	
Albuterol	Ethinyl estradiol/norethindrone <sup>b</sup>	
	Ibuprofen	

<sup>a</sup>Based on weighted number of women reporting use; listed in descending order

<sup>b</sup>Combination product

<sup>c</sup>Became available without a prescription in 2006

<sup>d</sup>GED: General Education Development or other comparable high school equivalency degree

<sup>e</sup>Poverty income ratio is an index for the ratio of family income to poverty, using poverty guidelines from the Department of Health and Human Services (23).